We are live on
!
Find out more
TA
Tamarack Advisers Portfolio holdings
AUM
$2.12M
1-Year Est. Return
58.09%
This Fund
S&P 500
This Quarter
Est. Return
+33.49%
1 Year Est. Return
-58.09%
3 Year Est. Return
-46.51%
5 Year Est. Return
+44.44%
10 Year Est. Return
–
AUM
$359M
AUM Growth
+$95.1M
(+36%)
Cap. Flow
+$16.4M
Cap. Flow
% of AUM
4.56%
Top 10 Holdings %
Top 10 Hldgs %
56.75%
Holding
42
New
11
Increased
10
Reduced
11
Closed
9
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ICU Medical
ICUI
|
+$13.3M |
| 2 |
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
|
+$10.2M |
| 3 |
UnitedHealth
UNH
|
+$10M |
| 4 |
Lantheus
LNTH
|
+$9.91M |
| 5 |
Labcorp
LH
|
+$8.86M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AtriCure
ATRC
|
+$16.3M |
| 2 |
Viatris
VTRS
|
+$8.1M |
| 3 |
MDRX
Veradigm Inc. Common Stock
MDRX
|
+$7.84M |
| 4 |
Medtronic
MDT
|
+$7.19M |
| 5 |
CHNG
Change Healthcare Inc. Common Stock
CHNG
|
+$6.99M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 90% |
| 2 | Technology | 5.35% |
| 3 | Materials | 1.59% |
| 4 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Pacira BioSciences
PCRX
$1.04B
| $36.7M | 10.23% |
700,000
+150,000
| +27% | +$6.27M |
|
2
Quest Diagnostics
DGX
$25.7B
| $31.3M | 8.73% |
275,000
-42,000
| -13% | -$4.45M |
|
3
Perrigo
PRGO
$1.4B
| $26.3M | 7.31% |
475,000
+75,000
| +19% | +$3.95M |
|
4
United Therapeutics
UTHR
$25.8B
| $21.2M | 5.9% |
175,000
+14,000
| +9% | +$1.58M |
|
|
HOLX
5
DELISTED
Hologic
HOLX
| $18.5M | 5.16% |
325,000
-55,000
| -14% | -$2.7M |
|
|
NUAN
6
DELISTED
Nuance Communications, Inc.
NUAN
| $14.6M | 4.05% |
575,000
-50,000
| -8% | -$1.04M |
|
|
7
ICU Medical
ICUI
$4.21B
| $14.4M | 4% |
78,000
+67,000
| +609% | +$13.3M |
|
|
8
Medtronic
MDT
$109B
| $13.8M | 3.83% |
150,000
-75,000
| -33% | -$7.19M |
|
|
9
Lantheus
LNTH
$6.49B
| $13.6M | 3.78% |
950,000
+750,000
| +375% | +$9.91M |
|
10
Bio-Rad Laboratories Class A
BIO
$8.71B
| $13.5M | 3.77% |
30,000
-10,000
| -25% | -$4.41M |
|
11
Rigel Pharmaceuticals
RIGL
$681M
| $12.5M | 3.49% |
685,000
+130,000
| +23% | +$2.34M |
|
|
OPTN
12
DELISTED
OptiNose
OPTN
| $11.3M | 3.16% |
101,667
-1,666
| -2% | -$119K |
|
13
Phreesia
PHR
$663M
| $11.3M | 3.15% |
400,000
+150,000
| +60% | +$3.91M |
|
14
RadNet
RDNT
$5.02B
| $11.1M | 3.09% |
700,000
+475,000
| +211% | +$6.88M |
|
|
GWPH
15
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $11M | 3.08% |
+90,000
| New | +$10.2M |
|
|
MDRX
16
DELISTED
Veradigm Inc. Common Stock
MDRX
| $10.8M | 3.02% |
1,600,000
-1,210,000
| -43% | -$7.84M |
|
|
17
UnitedHealth
UNH
$376B
| $10.3M | 2.87% |
+35,000
| New | +$10M |
|
|
18
AtriCure
ATRC
$1.92B
| $10.1M | 2.82% |
225,000
-375,000
| -63% | -$16.3M |
|
|
19
Labcorp
LH
$25B
| $9.14M | 2.54% |
+64,020
| New | +$8.86M |
|
20
CALL
SPDR Gold Trust
GLD
$131B
| $8.21M | 2.29% |
4,000
+500
| +14% | +$80.6K |
|
21
Abbott
ABT
$183B
| $6.86M | 1.91% |
+75,000
| New | +$6.78M |
|
|
22
Viatris
VTRS
$20.4B
| $6.43M | 1.79% |
400,000
-500,000
| -56% | -$8.1M |
|
|
STRM
23
DELISTED
Streamline Health Solutions
STRM
| $5.73M | 1.59% |
287,059
| – | – |
|
|
AMRS
24
DELISTED
Amyris Inc.
AMRS
| $5.69M | 1.59% |
+1,333,333
| New | +$4.43M |
|
|
ISEE
25
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $5.1M | 1.42% |
1,000,000
-250,000
| -20% | -$1.04M |
|
Similar funds
SCM
LBC
ICM
LCMP
GIP
STC
GC
DU
Tamarack Advisers's Q2 2020 Portfolio in Review
As of Q2 2020, Tamarack Advisers held 42 positions worth $359M, up 36% from $264M the previous quarter. Its ten largest holdings account for 57% of the portfolio.
Tamarack Advisers deployed $16.4M of net new capital in Q2 2020, opening 11 new positions and adding to 10 existing holdings. Its largest new stake was GW Pharmaceuticals Plc American Depositary Shares: 90,000 shares worth $11M.
By sector, the portfolio is most concentrated in Healthcare at 90% of assets, down from 91% a quarter earlier, followed by Technology and Materials.
On the sell side, the largest reduction was AtriCure, an estimated $16.3M trimmed.
- Tamarack Advisers's largest Q2 2020 buy was GW Pharmaceuticals Plc American Depositary Shares: 90,000 shares worth $11M.
- Tamarack Advisers added most to ICU Medical in Q2 2020, an estimated $13.3M increase.
- Tamarack Advisers's biggest Q2 2020 reduction was AtriCure, cutting an estimated $16.3M.
- Tamarack Advisers fully exited Change Healthcare Inc. Common Stock in Q2 2020, selling an estimated $6.99M.
- Tamarack Advisers's ten largest holdings make up 57% of its $359M portfolio in Q2 2020.
- Tamarack Advisers opened 11 new positions and closed 9 in Q2 2020.
- Tamarack Advisers's portfolio value rose 36% quarter-over-quarter to $359M.
Based on Tamarack Advisers's 13F filing for Q2 2020, filed 11 Aug 2020.